+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 50Years - 90Years
FEMALE
ID06938152

Comparing 2-Year Cyclic Therapy Versus 1-Year Romosozumab Followed by 1-Year Denosumab for Postmenopausal Osteoporosis

Led by National Taiwan University Hospital · Updated on 2026-06-23

70

Participants Needed

1

Research Sites

35 weeks

Total Duration

AI-Summary

What This Trial Is About

The trial investigates treatment approaches for osteoporosis in postmenopausal women aged 50 to 90 years. It compares a 24-month cyclic therapy regimen of Romosozumab followed by Denosumab repeated twice versus a traditional sequential therapy of 12 months Romosozumab followed by 12 months Denosumab. Osteoporosis is common in this population and can lead to fractures that reduce quality of life and increase mortality. The study aims to optimize drug strategies to improve patient outcomes. Participants will receive either Romosozumab monthly for 12 months followed by Denosumab every six months for 12 months, or a cycle therapy where Romosozumab is given monthly for 6 months, followed by one dose of Denosumab, then repeated once more after 6 months. This randomized controlled trial evaluates which regimen better affects bone health over two years. Throughout the study, participants will undergo bone mineral density BMD assessments at baseline and every 6 months up to 24 months. Bone turnover markers, pain levels via visual analogue scale, disability index scores, fracture occurrence, and adverse events will also be monitored at various intervals. This detailed monitoring supports evaluation of treatment efficacy and safety during the 24-month intervention period.

CONDITIONS

Brief Title

Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients

Research Team

F

Fon-Yih Tsuang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here